Binary events are an integral part of biotech investing; positive results from a clinical study can send shares soaring, while negative results can send a stock into a steep downward spiral.
Unfortunately, shareholders of drug developer Celsion (CLSN 10.77%) experienced the latter today. The company announced that its experimental liver cancer therapeutic, ThermoDox, failed to meet its primary endpoint in a pivotal phase 3 clinical trial. Health care analyst Max Macaluso breaks down this story in the following segment.
